Format

Send to

Choose Destination
Cancer Sci. 2017 Nov;108(11):2107-2114. doi: 10.1111/cas.13352. Epub 2017 Sep 5.

Long non-coding RNAs and prostate cancer.

Author information

1
Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
2
Department of Functional Biogerontology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
3
Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan.

Abstract

Long non-coding RNAs (lncRNAs) are RNA transcripts larger than 200 nucleotides that do not code for proteins the aberrant expression of which has been documented in various types of cancer, including prostate cancer. Lack of appropriate sensitive and specific biomarkers for prostate cancer has led to overdiagnosis and overtreatment, making lncRNAs promising novel biomarkers as well as therapeutic targets for the disease. The present review attempts to summarize the current knowledge of lncRNA expression patterns and mechanisms in prostate cancer, which contribute to carcinogenesis. In particular, we focused on lncRNAs regulated by androgen receptor and expressed in castration-resistant prostate cancer.

KEYWORDS:

Androgen; androgen receptor; castration resistant prostate cancer; long non-coding RNA; prostate cancer

PMID:
28796922
PMCID:
PMC5665759
DOI:
10.1111/cas.13352
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center